{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:15:54Z","timestamp":1788506154464,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aocs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Lipids"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors represent a novel approach for reducing cholesterol and, accordingly, the burden of atherosclerosis. However, limited data are available regarding the possible effects of PCSK9 inhibitors on atherosclerotic plaque. To evaluate the efficacy of PCSK9 inhibitors in reducing carotid plaque progression in individuals with high\u2010risk carotid atherosclerotic disease. We used carotid total plaque area (TPA) to assess the burden of atherosclerosis. Ultrasound imaging of the carotid was acquired before and after the initiation of PCSK9 inhibitor therapy. We selected high\u2010risk cases with atherosclerosis with a minimum of three ultrasound examinations, 1\u2009year before, one at the time of initiation of a PCSK9 inhibitor, and 1\u2009year after initiating a PCSK9 inhibitor. Statistical analysis was conducted using the mixed\u2010effects model with Restricted Maximum Likelihood (REML). We reviewed data from 131 patients with a mean follow\u2010up of 6 (\u00b14) years. Patients were high\u2010risk, with the majority having diabetes or hypertension. There was a decrease in TPA, particularly during the first 3\u2009years after initiating PCSK9 inhibitor therapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Furthermore, we observed that individuals with higher baseline serum low\u2010density lipoprotein cholesterol (LDL\u2010C) levels experienced a greater decline in TPA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). PCSK9 inhibitors are effective in achieving plaque regression in high\u2010risk patients with atherosclerosis. This is important, as plaque regression is associated with a lower risk of stroke, myocardial infarction, or vascular death.<\/jats:p>","DOI":"10.1002\/lipd.12432","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T03:35:27Z","timestamp":1737516927000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regression of carotid atherosclerosis in high\u2010risk individuals with proprotein convertase subtilisin\/kexin type 9 inhibitors"],"prefix":"10.1002","volume":"60","author":[{"given":"Albert Z.","family":"Luu","sequence":"first","affiliation":[{"name":"Schulich School of Medicine &amp; Dentistry Western University  London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Hajiesmaeili","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine &amp; Dentistry Western University  London Canada"},{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sholeh","family":"Faezi","sequence":"additional","affiliation":[{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"},{"name":"Neuroscience and Stroke Program Dr. Everett Chalmers Regional Hospital  Fredericton New Brunswick Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Spence","sequence":"additional","affiliation":[{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"},{"name":"Department of Medicine, Schulich School of Medicine &amp; Dentistry Western University  London Ontario Canada"},{"name":"Department of Clinical Neurological Sciences Western University  London Ontario Canada"},{"name":"Division of Clinical Pharmacology Department of Medicine Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Hackam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine &amp; Dentistry Western University  London Ontario Canada"},{"name":"Department of Clinical Neurological Sciences Western University  London Ontario Canada"},{"name":"Division of Clinical Pharmacology Department of Medicine Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Hadizadeh","sequence":"additional","affiliation":[{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"},{"name":"Department of Clinical Neurological Sciences Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed M.","family":"Sohrevardi","sequence":"additional","affiliation":[{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"},{"name":"School of Medicine Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Reza","family":"Azarpazhooh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine &amp; Dentistry Western University  London Canada"},{"name":"Stroke Prevention and Atherosclerosis Research Centre (SPARC), Robarts Research Institute Western University  London Ontario Canada"},{"name":"Department of Clinical Neurological Sciences Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001080"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2021.12.016"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715010-00004"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155928"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.999224"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781315183084"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/17539447231194861"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123023"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.487264"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.05.008"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13310"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5218"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.04.014"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3909\/ricm19S1S0002"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000706"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.289"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000042207.16156.B9"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.577973"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017392"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.08.002"}],"container-title":["Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aocs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lipd.12432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:27:03Z","timestamp":1760956023000},"score":1,"resource":{"primary":{"URL":"https:\/\/aocs.onlinelibrary.wiley.com\/doi\/10.1002\/lipd.12432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/lipd.12432"],"URL":"https:\/\/doi.org\/10.1002\/lipd.12432","archive":["Portico"],"relation":{},"ISSN":["0024-4201","1558-9307"],"issn-type":[{"value":"0024-4201","type":"print"},{"value":"1558-9307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"2024-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}